Last reviewed 2026-04-20 · How we verify

Magnacort (HYDROCORTAMATE)

Hydrocortamate (Magnacort), marketed by Pfizer, is a glucocorticoid receptor binder used primarily for treating inflammatory and immune conditions, competing in a crowded market with several off-patent generics. Its key strength lies in its mechanism of action, which effectively modulates gene expression related to inflammation and immune response. The primary risk is the expiration of its key composition patent in 2028, which could lead to increased competition from generics.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
• Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
• A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
• Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
• Corticosteroid Tapering in Sarcoidosis (NA)
• Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome (PHASE2)
• A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
• IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.